The peroxisome proliferator-activated receptors in cardiovascular diseases: Experimental benefits and clinical challenges

Wai San Cheang, Xiao Yu Tian, Wing Tak Wong, Yu Huang

Research output: Contribution to journalReview article

31 Scopus citations

Abstract

The peroxisome proliferator-activated receptors, PPARα, PPARβ/δ and PPARγ, are ligand-activated transcriptional factors belonging to the nuclear receptors superfamily and they are known to play important roles in glucose and lipid metabolism. Experimental studies in animal models of metabolic diseases have also revealed that activation of PPARs protects against the vascular complications of diabetes, hypertension, atherosclerosis, myocardial infarction and stroke, through exerting their anti-inflammatory, anti-atherogenic and antioxidant effects. In clinical trials and post-market surveillance, agonists of PPARs have been shown to effectively prevent cardiovascular events. However, adverse effects, particularly for PPARγ agonists, are also observed with the use of investigational PPAR agonists and even some approved drugs. Further exploration of underlying mechanisms is needed to develop novel ways of PPAR activation without causing serious side effects. This article reviews the cardiovascular effects of PPARs, with emphasis on the therapeutic potential of PPAR agonists in combating metabolic vascular diseases.

Original languageEnglish (US)
Pages (from-to)5512-5522
Number of pages11
JournalBritish Journal of Pharmacology
Volume172
Issue number23
DOIs
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The peroxisome proliferator-activated receptors in cardiovascular diseases: Experimental benefits and clinical challenges'. Together they form a unique fingerprint.

Cite this